Science Explorer Interactive view Map
Company · Maastricht · Netherlands

ACS Biomarker (Netherlands)

Research works
1
▲ 72% vs 2013–17
Citations
21
19.3 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
74%
world 28%

Not ranked overall: ACS Biomarker (Netherlands) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which research topics does ACS Biomarker (Netherlands) publish most on?

By volume in 2022–2025: Multiple Myeloma Research and Treatments, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research and Single-cell and spatial transcriptomics.

  1. 1 Multiple Myeloma Research and Treatments Hematology 0 works
  2. 2 Chronic Myeloid Leukemia Treatments Hematology 0 works
  3. 3 Acute Myeloid Leukemia Research Hematology 0 works
  4. 4 Single-cell and spatial transcriptomics Molecular Biology 0 works
  5. 5 Glioma Diagnosis and Treatment Genetics 0 works
  6. 6 Neutropenia and Cancer Infections Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available74.0%not open26.0%

World: 28% of research is openly available.

with international co-authors84.7%domestic only15.3%

World: 19% is written across borders.

How has ACS Biomarker (Netherlands)'s research output changed?

Output in 2018–2022 was 72% higher than in 2013–2017.

2020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Maastricht

All research institutions in Maastricht

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.